✦ LIBER ✦

Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors

✍ Scribed by Yulia Lin; Hélène Bruyère; Douglas E. Horsman; Tapio Pantzar; Michael J. Barnett; Donna E. Hogge; Thomas J. Nevill; Stephen H. Nantel; Heather J. Sutherland; Cynthia L. Toze; John D. Shepherd; Julye C. Lavoie; Kevin W. Song; Clayton A. Smith; Donna L. Forrest

Book ID: 113512959
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 165 KB
Volume: 170
Category: Article
ISSN: 0165-4608
DOI: 10.1016/j.cancergencyto.2006.04.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Report of 34 patients with clonal chromo

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia

✍ Terre, C; Eclache, V; Rousselot, P; Imbert, M; Charrin, C; Gervais, C; Mozzicona 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 126 KB

Clonal chromosome aberrations in Philade

Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases

✍ Christian Herens; Frédéric Baron; Christiane Croisiau; Francoise Tassin; Vincent 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Occurrence of colon adenocarcinoma in ch

Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: Report of two cases and review of the literature

✍ A. Frustaci; M. Breccia; L. Cannella; C. Stefanizzi; G. Alimena 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Is it possible to discontinue imatinib m

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

✍ Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o

High-dose imatinib mesylate combined wit

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

✍ Rea, D; Legros, L; Raffoux, E; Thomas, X; Turlure, P; Maury, S; Dupriez, B; Pign 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 100 KB

Occurrence of high-grade T-Cell lymphoma

Occurrence of high-grade T-Cell lymphoma in a patient with philadelphia chromosome-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: Case report and review of the literature

✍ Benjamin Djulbegovic; Terence Hadley; Frank Yen 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB 👁 2 views